| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910590080403321 |
|
|
Autore |
Corasolla Carregari Victor |
|
|
Titolo |
Understanding PTMs in Neurodegenerative Diseases |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham : , : Springer International Publishing AG, , 2022 |
|
©2022 |
|
|
|
|
|
|
|
|
|
ISBN |
|
9783031054600 |
9783031054594 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (150 pages) |
|
|
|
|
|
|
Collana |
|
Advances in Experimental Medicine and Biology Ser. ; ; v.1382 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface -- Contents -- Chapter 1: Protein Extraction and Sample Preparation Methods for Shotgun Proteomics with Central Nervous System Cells and Brain Tissue -- 1.1 Introduction -- 1.2 Lysis Buffers -- 1.3 Buffer Compositions, Pros, and Cons -- 1.3.1 RIPA Buffer -- 1.3.2 Modified RIPA Buffer -- 1.3.3 SDS Sample Buffer -- 1.3.4 NP-40 Lysis Buffer -- 1.3.5 HEPES Lysis Buffer -- 1.3.6 CHAPS Lysis Buffer -- 1.3.7 Urea Buffer -- 1.3.8 Protease Inhibitor Cocktail -- 1.4 Sample Preparation Methods -- 1.4.1 Central Nervous System (CNS) Cells -- 1.4.2 Postmortem Brain Tissue -- 1.4.3 Cerebrospinal Fluid (CSF) -- 1.5 Digestion Methods for Shotgun Proteomics -- 1.5.1 In-Solution Digestion -- 1.5.2 Homemade C18 Microcolumn -- 1.5.3 Filter-Aided Sample Preparation (FASP) -- 1.5.4 Suspension Trap (S-TRAP) -- 1.6 Conclusions -- References -- Chapter 2: Phosphopeptide Enrichment Techniques: A Pivotal Step for Phosphoproteomic Studies -- 2.1 Introduction -- 2.2 Phosphopeptide Enrichment -- 2.3 IMAC -- 2.4 TiO2 -- 2.5 TiO2 Micro-Column -- 2.6 SIMAC -- 2.7 Conclusion -- References -- Chapter 3: Post-Translational Modifications During Brain Development -- 3.1 Biological Steps of Neurodevelopment and Post-translational Modifications -- 3.2 Post-translational Modifications During Neurodevelopment -- 3.2.1 Cytoskeletal Proteins -- 3.2.2 Gene Transcription and Protein Translation -- 3.2.3 Signaling Pathways -- 3.3 Concluding Remarks -- References -- Chapter 4: Aberrant Protein |
|
|
|
|
|
|
|
|
|
|
Glycosylation in Brain Cancers, with Emphasis on Glioblastoma -- 4.1 Introduction -- 4.2 Asparagine N-Linked Glycosylation Family (ALG) -- 4.3 β-1,4-Galactosyltransferase (B4T) and β-1,3-Nacetylglucosaminyltransferase (B3T) Families -- 4.4 Fucosyltransferase Family (FUT) -- 4.5 N-Acetylgalactosaminyltransferase Family (GALNT) -- 4.6 Hexosaminidase Family (HEX). |
4.7 Mannosidase Family (MAN) -- 4.8 N-Acetylglucosaminyltransferase Family (MGAT) -- 4.9 Sialidase Family (NEU) -- 4.10 Solute Carrier 35 Family (SLC35) -- 4.11 Sialyltransferase Family (ST) -- 4.12 Conclusions and Outlook -- References -- Chapter 5: Post-translational Modification in Muscular Dystrophies -- 5.1 Introduction -- 5.2 PTMs and Duchenne Muscular Dystrophy -- 5.3 Glycosylation of α-Dystroglycan in MDs -- 5.4 PTMs and Other Muscular Dystrophies -- 5.5 Muscular Dystrophy Treatments and PTMs -- 5.6 Conclusions -- References -- Chapter 6: Post-translational Modifications in Parkinson's Disease -- 6.1 Parkinson's Disease -- 6.1.1 Alpha-Synuclein Aggregation and Parkinson's Disease -- 6.1.2 Mitochondrial Dysfunction and Parkinson's Disease -- 6.2 Post-translational Modifications -- 6.2.1 Phosphorylation -- 6.2.2 Glycosylation -- 6.2.3 Acetylation -- 6.2.4 Ubiquitination -- 6.3 Mass Spectrometry in the Investigation of PTMs -- 6.4 PTMs and PD -- 6.4.1 Phosphorylation -- 6.4.2 Ubiquitination -- 6.4.3 Glycosylation -- 6.5 Conclusion -- References -- Chapter 7: Histone Modifications in Neurological Disorders -- 7.1 Histones and Their Modifications -- 7.2 Investigating Histone PTMs -- 7.3 Specific Roles in Neurological Disorders -- 7.3.1 Alzheimer's, Parkinson's, and Huntington's Diseases -- 7.4 Aging and Cognitive Decline -- 7.5 Cognition, Memory, and Neurodevelopment -- 7.6 Schizophrenia and Bipolar Disorder -- 7.7 Depression and Chronic Stress -- 7.8 Concluding Remarks -- References -- Chapter 8: Mitochondrial Dysregulation and the Influence in Neurodegenerative Diseases -- 8.1 Introduction -- 8.2 Neurodegenerative Diseases and Evidence of Mitochondrial Dysfunction -- 8.2.1 Parkinson's Disease -- 8.2.2 Alzheimer's Disease -- 8.2.3 Huntington's Disease -- 8.2.4 Amyotrophic Lateral Sclerosis -- 8.3 Concluding Remarks -- References. |
Chapter 9: PTMs: A Missing Piece for Schizophrenia Studies -- 9.1 Introduction -- 9.2 PTMs in the Pathophysiology of Schizophrenia -- 9.2.1 Phosphorylation -- 9.2.2 Glycosylation -- 9.2.3 Ubiquitination -- 9.2.4 Palmitoylation -- 9.3 Future Directions and Concluding Remarks -- References -- Chapter 10: Post-translational Modifications in Brain Diseases: A Future for Biomarkers -- 10.1 Introduction -- 10.2 PTM Types -- 10.3 Regulation -- 10.4 PTMs in Brain Diseases -- 10.4.1 Neurodegenerative Disorders -- 10.4.2 Psychiatric Disorders -- 10.4.3 Aging and Cancer -- 10.5 Biomarker Sources -- 10.6 Concluding Remarks -- References -- Index. |
|
|
|
|
|
| |